Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.68 |
| ▸ | RECQL | P46063 | 1/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.59 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 2/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 3/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14132463 | 0.97 | SMN1; SMN2 (0.73) | SMN1; SMN2KDM4ERECQLALDH1A1CYP3A4 | |
| SCHEMBL23806536 | 0.95 | SMN1; SMN2 (0.71) | SMN1; SMN2KDM4ERECQLALDH1A1CYP3A4 | |
| SCHEMBL14132621 | 0.95 | SMN1; SMN2 (0.71) | SMN1; SMN2KDM4ERECQLALDH1A1CYP3A4 | |
| SCHEMBL12352556 | 0.93 | UCHL1 (0.62) | SMN1; SMN2KDM4ERECQLALDH1A1CYP3A4 | |
| SCHEMBL20082404 | 0.86 | UCHL1 (0.55) | SMN1; SMN2KDM4ERECQLALDH1A1CYP3A4 | |
| SCHEMBL14537 | 0.86 | UCHL1 (0.55) | SMN1; SMN2KDM4ERECQLALDH1A1CYP3A4 | |
| SCHEMBL14923992 | 0.84 | USP30 (0.64) | SMN1; SMN2KDM4ERECQLALDH1A1CYP3A4 | |
| SCHEMBL20082432 | 0.84 | SMN1; SMN2 (0.51) | SMN1; SMN2KDM4ERECQLALDH1A1CYP3A4 | |
| SCHEMBL14924007 | 0.83 | UCHL1 (0.63) | SMN1; SMN2KDM4ERECQLALDH1A1CYP3A4 | |
| SCHEMBL23052023 | 0.82 | UCHL1 (0.62) | SMN1; SMN2KDM4ERECQLALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10626111-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2020-04-21 | — | — | US | disclosed |
| US-8324207-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-12-04 | — | — | US | disclosed |
| EP-2404919-A1 | Pharmaceutical composition containing a heterocyclic modulator of ATP-binding cassette transporters. | Vertex Pharmaceuticals Incorporated (US) | 2012-01-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10626111-B2 | Modulators of ATP-binding cassette transporters | CFTR, ABCB1, ABCC2 | SMN1; SMN2 4829/4885KDM4E 4026/4885RECQL 606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.